Prevention of Cardiovascular Disease Using a Single PolyPill in an Urban Population - Focus on Liver-Related Variables.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2400 participants.

Also called NCT01245608

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 2,400 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01245608
Other papers using this trial's data
  • Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial European heart journal, 2022-06-01 DOI, PubMed 35048107

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Iran (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01245608. Randomized; single masking; primary purpose prevention. Start 2011-10 (actual); primary completion 2018-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Prevention of Cardiovascular Disease Using a Single PolyPill in an Urban Population - Focus on Liver-Related Variables.
Acronym
PolyIran-L
Condition
Cardiovascular Diseases
Intervention (Drug)
Polypill
Lead sponsor
Tehran University of Medical Sciences (class: other)
Collaborator
Golestan University of Medical sciences (class: other)
Collaborator
University of Birmingham (class: other)

Record details

Record id
cardio:ct-nct01245608
Content hash
bd2fd22b0087f1a5e1426f6e911aef83978f3ce35ba0f2629447f6333d411943